Lista de obras -

A method for assessing the quality of life of cancer patients: replication of the factor structure ⬇️

artículo científico publicado el 1 de junio de 1992

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study.

artículo científico publicado en 2015

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

artículo científico publicado en 2004

Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Accelerated partial breast irradiation: more questions than answers?

scientific article published on 05 December 2019

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c ⬇️

article

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

scientific article published on April 2016

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

artículo científico publicado en 2015

Adjuvant psychological therapy for patients with cancer: a prospective randomised trial ⬇️

artículo científico publicado el 14 de marzo de 1992

Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up.

artículo científico publicado en 2015

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

artículo científico publicado en 2014

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

artículo científico publicado en 2019

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

artículo científico publicado en 2014

Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.

artículo científico publicado en 2015

Biomarker-guided trials: Challenges in practice

scientific article published on 16 November 2019

Bone marrow micrometastases in early breast cancer-30-year outcome

artículo científico publicado en 2016

Breast cancer and hormone-replacement therapy: the Million Women Study

artículo científico publicado en 2003

Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?

artículo científico publicado en 2018

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial

artículo científico publicado en 2019

Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.

artículo científico publicado en 2017

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

artículo científico publicado en 2018

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

artículo científico publicado en 2012

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

scientific article published on 31 May 2019

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00

artículo científico publicado en 2014

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials

artículo científico publicado en 2010

Conducting non-commercial international clinical trials: the ICR-CTSU experience

artículo científico publicado en 2017

Design and Rationale of a Randomised Comparison of Cyclophosphamide, Methotrexate and Fluorouracil vs Fluorouracil, Epirubicin and Cyclophosphamide in Node-Positive Premenopausal Women with Operable Breast Cancer

artículo científico publicado el 1 de enero de 1993

Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).

artículo científico publicado en 2015

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study

artículo científico publicado en 2011

Dissecting the heterogeneity of triple-negative breast cancer

artículo científico

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES

artículo científico publicado en 2019

Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer

artículo científico publicado en 2016

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer ⬇️

artículo científico publicado en 2012

ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials

artículo científico publicado en 2020

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

artículo científico publicado en 2018

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

artículo científico publicado en 2006

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer

artículo científico publicado en 2016

Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial ⬇️

artículo científico publicado el 7 de febrero de 1998

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. ⬇️

artículo científico publicado en 2017

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic

scientific article published on 08 June 2020

Excision margins in high-risk malignant melanoma

artículo científico publicado en 2004

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

artículo científico publicado en 2018

Exploring the role and function of trial steering committees: results of an expert panel meeting

artículo científico publicado en 2015

Exploring the role and functionality of trial steering committees.

artículo científico publicado en 2015

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

artículo científico publicado en 2011

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial

artículo científico publicado en 2015

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

artículo científico publicado en 2018

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

artículo científico publicado en 2011

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

artículo científico publicado en 2013

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

scientific article published on 12 June 2019

Genomic profile of advanced breast cancer in circulating tumour DNA

artículo científico publicado en 2021

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

artículo científico publicado en 2015

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

artículo científico publicado en 2016

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

artículo científico publicado en 2020

How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction)

artículo científico publicado en 2016

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

artículo científico publicado en 2007

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

artículo científico publicado en 2020

Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues

artículo científico publicado en 2015

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts ⬇️

artículo científico publicado el 1 de enero de 1997

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

scientific article published on 31 December 2019

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

artículo científico publicado en 2016

Implementing electronic data capture (EDC) training for site staff.

artículo científico publicado en 2015

In Regard to Vaidya et al

scientific article published on 14 July 2015

Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort

artículo científico publicado en 2005

Intraoperative radiotherapy for early breast cancer

artículo científico publicado en 2010

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries

artículo científico publicado en 2010

Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial

artículo científico publicado en 2019

Late effects of breast radiotherapy

artículo científico publicado en 2014

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.

artículo científico publicado en 2017

Long-Term Follow-Up of the Intergroup Exemestane Study ⬇️

artículo científico publicado en 2017

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer

artículo científico publicado en 2018

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC).

artículo científico publicado en 2015

Multidisciplinary urological engagement in translational renal cancer research

artículo científico publicado en 2014

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

artículo científico publicado en 2014

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

artículo científico

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

artículo científico publicado en 2018

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial

artículo científico publicado en 2018

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

artículo científico

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

artículo científico

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†. ⬇️

artículo científico publicado en 2015

Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.

artículo científico publicado en 2016

QUEST Perspective Study (QPS) to measure the understanding by patients and healthcare professionals of surgical breast reconstruction clinical trials: QUEST Trials A & B.

artículo científico publicado en 2011

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

artículo científico publicado en 2006

Radiotherapy for breast cancer, the TARGIT-A trial

artículo científico publicado en 2014

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

scientific article published on 06 December 2018

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer

artículo científico publicado en 2011

Reply to Goodare et al. Re: Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy?

artículo científico publicado en 2016

Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis

artículo científico publicado en 2016

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

artículo científico publicado en 2010

Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma ⬇️

artículo científico publicado el 23 de mayo de 1992

Safety of exemestane in the Intergroup Exemestane Study

artículo científico publicado en 2005

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

scientific article published on May 2009

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

artículo científico publicado en 2007

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).

artículo científico publicado en 2017

Targeted radiotherapy for early breast cancer - Authors' reply

artículo científico publicado en 2018

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

artículo científico publicado en 2020

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.

artículo científico publicado en 2017

The MARS feasibility trial: conclusions not supported by data – Authors' reply

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

artículo científico publicado en 2013

The Value of Patient and Public Involvement in Trial Design and Development

article

The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective.

artículo científico publicado en 2014

The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START).

artículo científico publicado en 2009

The development of a DVD to aid patients’ understanding of surgical breast reconstruction clinical trials: QUEST Trials A & B.

artículo científico publicado en 2011

The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).

artículo científico publicado en 2007

The impact of nausea and vomiting upon quality of life measures ⬇️

artículo científico publicado el 1 de diciembre de 1992

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial

artículo científico publicado en 2016

Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer.

artículo científico publicado en 2018

XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients

artículo científico publicado en 2015

Lista de obras de

A method for assessing the quality of life of cancer patients: replication of the factor structure ⬇️

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Accelerated partial breast irradiation: more questions than answers?

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c ⬇️

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Adjuvant psychological therapy for patients with cancer: a prospective randomised trial ⬇️

Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.

Biomarker-guided trials: Challenges in practice

Bone marrow micrometastases in early breast cancer-30-year outcome

Breast cancer and hormone-replacement therapy: the Million Women Study

Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial

Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials

Conducting non-commercial international clinical trials: the ICR-CTSU experience

Design and Rationale of a Randomised Comparison of Cyclophosphamide, Methotrexate and Fluorouracil vs Fluorouracil, Epirubicin and Cyclophosphamide in Node-Positive Premenopausal Women with Operable Breast Cancer

Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study

Dissecting the heterogeneity of triple-negative breast cancer

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES

Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer ⬇️

ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer

Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial ⬇️

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. ⬇️

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic

Excision margins in high-risk malignant melanoma

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

Exploring the role and function of trial steering committees: results of an expert panel meeting

Exploring the role and functionality of trial steering committees.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

Genomic profile of advanced breast cancer in circulating tumour DNA

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction)

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts ⬇️

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Implementing electronic data capture (EDC) training for site staff.

In Regard to Vaidya et al

Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort

Intraoperative radiotherapy for early breast cancer

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries

Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial

Late effects of breast radiotherapy

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.

Long-Term Follow-Up of the Intergroup Exemestane Study ⬇️

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC).

Multidisciplinary urological engagement in translational renal cancer research

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.